Search research articles
Contact Us
Filters
Showing results (151-160 of 203) with videos related to
Page
of 21
Sort By:
Inflammatory Bowel Diseases
|
June 12, 2019
Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
Diana M Negoescu, Eva A Enns, Brooke Swanhorst, et al.
Inflammatory Bowel Diseases
|
July 18, 2014
High self-efficacy predicts adherence to surveillance colonoscopy in inflammatory bowel disease
Sonia Friedman, Adam S Cheifetz, Francis A Farraye, et al.
Journal of Crohn'S & Colitis
|
March 18, 2019
The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis
Bruce E Sands, Adam S Cheifetz, Chudy I Nduaka, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 27, 2015
Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice
Joseph D Feuerstein, Natalia E Castillo, Sana S Siddique, et al.
Journal of Clinical Medicine
|
December 10, 2021
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
Rodrigo Bremer Nones, Phillip R Fleshner, Natalia Sousa Freitas Queiroz, et al.
Igie : Innovation, Investigation and Insights
|
July 3, 2026
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitment
Laurie B Grossberg, Grace Geeganage, Aditya Mithal, et al.
Journal of Clinical Medicine
|
September 5, 2020
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
Konstantinos Papamichael, Valerio J Thomas, Andrea Banty, et al.
Inflammatory Bowel Diseases
|
February 27, 2020
Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey
Lisa Malter, Animesh Jain, Benjamin L Cohen, et al.
The American Journal of Gastroenterology
|
November 26, 2024
Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study
Adam S Cheifetz, Jessica R Allegretti, Megan Quintas, et al.
Inflammatory Bowel Diseases
|
September 28, 2019
Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study
William T Clarke, Konstantinos Papamichael, Niels Vande Casteele, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 203) with videos related to
Sort By:
Page
of 21
Inflammatory Bowel Diseases
|
June 12, 2019
Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
Diana M Negoescu, Eva A Enns, Brooke Swanhorst, et al.
Inflammatory Bowel Diseases
|
July 18, 2014
High self-efficacy predicts adherence to surveillance colonoscopy in inflammatory bowel disease
Sonia Friedman, Adam S Cheifetz, Francis A Farraye, et al.
Journal of Crohn'S & Colitis
|
March 18, 2019
The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis
Bruce E Sands, Adam S Cheifetz, Chudy I Nduaka, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 27, 2015
Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice
Joseph D Feuerstein, Natalia E Castillo, Sana S Siddique, et al.
Journal of Clinical Medicine
|
December 10, 2021
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
Rodrigo Bremer Nones, Phillip R Fleshner, Natalia Sousa Freitas Queiroz, et al.
Igie : Innovation, Investigation and Insights
|
July 3, 2026
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitment
Laurie B Grossberg, Grace Geeganage, Aditya Mithal, et al.
Journal of Clinical Medicine
|
September 5, 2020
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
Konstantinos Papamichael, Valerio J Thomas, Andrea Banty, et al.
Inflammatory Bowel Diseases
|
February 27, 2020
Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey
Lisa Malter, Animesh Jain, Benjamin L Cohen, et al.
The American Journal of Gastroenterology
|
November 26, 2024
Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study
Adam S Cheifetz, Jessica R Allegretti, Megan Quintas, et al.
Inflammatory Bowel Diseases
|
September 28, 2019
Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study
William T Clarke, Konstantinos Papamichael, Niels Vande Casteele, et al.
Page
of 21